About Cellares
Cellares is a company based in San Francisco (United States) founded in 2019 by Fabian Gerlinghaus and Omar Kurdi. Cellares has raised $682 million across 6 funding rounds from investors including Bristol-Myers Squibb, Koch Disruptive Technologies and DFJ Growth. Cellares operates in a competitive market with competitors including 10X Genomics, Mission Bio, LUMICKS, LevitasBio and Rebus Biosystems, among others.
- Headquarter San Francisco, United States
- Founders Fabian Gerlinghaus, Omar Kurdi
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$682 M (USD)
in 6 rounds
-
Latest Funding Round
$50 M (USD), Series D
Jun 15, 2026
-
Investors
Bristol-Myers Squibb
& 19 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cellares
Unlock access to complete
Unlock access to complete
Funding Insights of Cellares
Cellares has successfully raised a total of $682M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $50 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cellares
Cellares has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include Bristol-Myers Squibb, Koch Disruptive Technologies and DFJ Growth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by the venture capital firm.
|
Locked | Locked | Locked | |
|
Investments are directed toward innovative technology startups by DFJ Growth.
|
Locked | Locked | Locked | |
|
Philanthropic assets are managed by Willett Advisors LLC.
|
Locked | Locked | Locked |
Investor details for Cellares
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellares
Investment portfolio details for Cellares
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellares
Detailed financials for Cellares
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellares Comparisons
Peer comparison for Cellares
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellares
Cellares operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, LUMICKS, LevitasBio and Rebus Biosystems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Instrument systems for genomic research and sequencing libraries are developed.
|
|
| Locked | Locked | Locked |
Single-cell multi-omics platform is provided for genotypic and phenotypic analysis.
|
|
| Locked | Locked | Locked |
Optical tweezers instruments for single-molecule analysis are manufactured.
|
|
| Locked | Locked | Locked |
Single-cell imaging platform developed via magnetic levitation technology.
|
|
| Locked | Locked | Locked |
An imaging system for single-cell gene analysis is developed.
|
Detailed competitors of Cellares
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellares
Complete news archive for Cellares
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellares
Cellares was founded in 2019.
Cellares is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Fabian Gerlinghaus is the current CEO of Cellares. They have also founded this company.
Cellares is a funded company, having raised a total of $682M across 6 funding rounds to date.
Cellares was founded in 2019 and is based in San Francisco, United States. Operations focus on the biotechnology sector, where medical devices for cell-based therapy are manufactured. The Cell Shuttle platform is provided, integrating technologies for automated, end-to-end manufacturing processes with high throughput. A software suite supporting various cell therapy modalities is also offered to facilitate production workflows.
Cellares's top competitors include 10X Genomics, Mission Bio and LUMICKS.
Cellares has 20 investors. Key investors include Bristol-Myers Squibb, Koch Disruptive Technologies, DFJ Growth, Willett Advisors, and Eclipse.